Pliant Therapeutics stock hits 52-week low at 10.24 - Investing.com

PLRX Stock  USD 13.18  0.12  0.90%   
Slightly above 55% of Pliant Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Pliant Therapeutics suggests that many traders are impartial. Pliant Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Pliant Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Pliant Therapeutics stock hits 52-week low at 10.24 Investing.com

Read at news.google.com
Google News at Macroaxis
  

Pliant Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Pliant Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pliant Therapeutics Fundamental Analysis

We analyze Pliant Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pliant Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pliant Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Shares Shorted

Number Of Shares Shorted Comparative Analysis

Pliant Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Pliant Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pliant Therapeutics stock to make a market-neutral strategy. Peer analysis of Pliant Therapeutics could also be used in its relative valuation, which is a method of valuing Pliant Therapeutics by comparing valuation metrics with similar companies.

Peers

Pliant Therapeutics Related Equities

CYTKCytokinetics   4.75   
0%
53.0%
VRDNViridian Therapeutics   4.13   
0%
46.0%
INZYInozyme Pharma   3.20   
0%
35.0%
STOKStoke Therapeutics   1.71   
0%
19.0%
RLAYRelay Therapeutics   1.43   
0%
15.0%
RVMDRevolution Medicines   1.11   
0%
12.0%
ACLXArcellx   0.56   
0%
6.0%
SNDXSyndax Pharmaceuticals   0.47   
0%
5.0%
MDGLMadrigal Pharmaceuticals   0.22   
0%
2.0%
ARVNArvinas   4.19   
46.0%
0%
DYNDyne Therapeutics   6.12   
68.0%
0%
BDTXBlack Diamond   6.40   
71.0%
0%
ETNB89bio   7.62   
85.0%
0%
PASGPassage Bio   8.96   
100.0%
0%

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.